News

The study finds that treatment resulted in a significant visual improvement.

‘From the Bench to Bedside and Back’ is focal point for this year’s conference

Group of researchers aim to validate both approaches in proof-of-concept study

One biologic response modifier has indication for uveitis; several in development to gain FDA approval

Quiescence, steroid-free quiescence achieved in VISUAL III trial

FA implant effective in lowering recurrence rates through available 6, 12 months of follow-up

Improvement in visual acuity, central retinal thickness, vitreous haze reported at 6 months

Intravitreal triamcinolone acetonide, dexamethasone implant superior for regional treatment of disorder

New research confirms agreement with 7 standard field imaging

FDA decision changes scope of healthcare delivery; increases patient access to early detection of DR

Fifteen fellows, residents showed just why research in retina is on the cutting edge